Compare Amazon.com Inc (AMZN) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amazon.com Inc vs Inovio Pharmaceuticals Inc — how do they compare? Amazon.com Inc trades at $267.39 (market cap $2.94T), while Inovio Pharmaceuticals Inc trades at $0.74 (market cap $78.55M). The key difference: Amazon.com Inc is far larger — about 37428.4× Inovio Pharmaceuticals Inc's market cap, and Amazon.com Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMZN | INO | |
|---|---|---|
Market Cap | $2.94T | $78.55M |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $284.02 | $2.87 |
52-Week Low | $198.79 | $0.66 |
Enterprise Value | $3.04T | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $272.27, down 2.09% today but maintains strong fundamentals with robust revenue growth from $638B in 2024 to $716.9B in 2025 and net income surging to $77.67B. Technical indicators show a bullish trend with support at $271 and resistance at $275, while analyst consensus remains overwhelmingly positive with 89% buy ratings and a $333.86 price target. Recent news highlights CEO Andy Jassy's optimistic outlook on AWS growth and AI chip business expansion.
Amazon presents a compelling investment case with accelerating profitability and dominant market positioning, though investors face risks from intense competition and significant capital expenditures. The stock's current valuation at 21.9x P/E appears reasonable given projected 2026 net income growth to $135.3B, supporting potential upside to analyst targets despite near-term market volatility.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
